


RESEARCH ARTICLE

 OPEN ACCESS

Received: 19-02-2023

Accepted: 03-07-2023

Published: 08-08-2023

Citation: Serawat KK, Meena KK, Gunsaria RK (2023) *In-Vitro* Studies on Alpha Amylase and Alpha Glucosidase Inhibitory Activities of Synthesized Novel Sn(IV) Complexes of Schiff Base Ligand. Indian Journal of Science and Technology 16(30): 2297-2303. <https://doi.org/10.17485/IJST/V16i30.370>

* Corresponding author.

kamalkantserawat2016@gmail.com

Funding: CSIR-UGC

Competing Interests: None

Copyright: © 2023 Serawat et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Published By Indian Society for Education and Environment ([iSee](https://www.isee.org/))

ISSN

Print: 0974-6846

Electronic: 0974-5645

In-Vitro Studies on Alpha Amylase and Alpha Glucosidase Inhibitory Activities of Synthesized Novel Sn(IV) Complexes of Schiff Base Ligand

Kamal Kant Serawat^{1*}, Kavita Kumari Meena¹, R K Gunsaria²

¹ Research Scholar, Department of Chemistry, University of Rajasthan, Jaipur, 302004, Rajasthan, India

² Associate Professor, Department of Chemistry, University of Rajasthan, Jaipur, 302004, Rajasthan, India

Abstract

Objectives: The current study is concerned with creating Sn(IV) complex with a novel synthesized schiff base ligand 2,3-dimethyl-N'-(2-oxo-2,3-dihydro-1H-indol-3-yl)benzhydrazide and were investigated for the inhibition of alpha-amylase and alpha-glucosidase enzyme. **Methods:** Ligand was synthesized by using isatin and 2,3-dimethylbenzoic acid hydrazide. n-Bu₃SnCl and n-Bu₂SnCl₂ were used for the synthesis of metal complexes. The structures of the ligand and metal complexes were confirmed by spectroscopic analysis i.e. ¹H-NMR, IR and MS. **Findings:** A clinical disease known as diabetes mellitus is defined by hyperglycemia, in which a greater than normal amount of glucose circulates in the blood plasma. Inhibitors of alpha amylase and alpha glucosidase are used to better manage hyperglycemia in type 2 diabetes mellitus. Synthesized metal complexes were investigated for the inhibition of alpha-amylase and alpha-glucosidase enzyme. In the alpha amylase inhibition assay, L-1 (118.88±11.14), MC-1 (76.90±9.55), and MC-2 (73.28±8.31) all displayed 50% alpha amylase inhibition activity. The IC₅₀ values for [L-1], [MC-1], and [MC-2] in the alpha glucosidase inhibition experiment were 128.86±10.27, 76.90±9.55, and 73.28±8.31 g/ml, respectively. Observed data revealed that MC-2 has higher inhibition activity. **Novelty:** Anti-hyperglycemia activity was investigated by using newly synthesized metal complexes.

Keywords: Schiff Base; Sn(IV); Hyperglycemia; Alpha Amylase; Alpha Glucosidase

1 Introduction

Metal complexes gain tremendous consideration in medicinal chemistry because of their marked and enormous biological properties⁽¹⁾. They are used as anticancer⁽²⁾, antimicrobial^(3,4), antiviral⁽⁵⁾, antiparasitic⁽⁶⁾, antimalarial⁽⁷⁾, antifungi⁽⁸⁾ agents. Significance of “coordination chemistry is escalating constantly with the synthesis of organic ligand/s containing” assorted donor groups⁽⁹⁾. Saroya and co-researchers

synthesized Diorganotin(IV) complexes with Schiff base ligands and found that ONO donor atoms served as the tridentate conduit. Synthesized complexes were tested for anti-bacterial and anti-fungal efficacy and reveal that phenyl-substituted complexes showing superior activity. Additionally, the complexes were tested for their anticancer activity, and one of the synthesized complexes exhibited the most potent effect against the A549 cell line, comparable to the standard drug paclitaxel⁽¹⁰⁾. Additionally, Saroya et al. synthesized organotin complexes of Schiff bases and exhibited pentacoordinated geometry. The complexes showed enhanced antimicrobial and antioxidant activity compared to the ligands. Ligands with electron-withdrawing groups demonstrated higher antimicrobial activity, while electron-donating groups increased antioxidant activity⁽¹¹⁾. Organometallic complexes offer multipurpose framework for drug designing. Synthesized metal complexes with different types of ligands tested for their cytotoxic activity and found highly cytotoxic against human tumor cell lines⁽¹²⁾. In addition to the exploration of organometallic complexes, Agarwal et al. focused on the recent advancements in the anticancer potentials of first-row transition metal complexes. Their study reviewed the progress made in utilizing transition metal complexes for cancer treatment⁽¹³⁾. Deswal and co-researchers explored the synthesis, spectral characterization, antimicrobial, anticancer, and molecular docking studies of transition metal complexes of triazole-based bioactive ligands and found that some of the complexes showed significant anticancer activity against the three tested cancer cell lines i.e. HCT-116, DU145, and A549. The docking results correlate very well with the IC₅₀ data and enabled the importance of interactions for depicting the binding energies of the potent compounds⁽¹⁴⁾. Further, copper(II) and tin(IV) complexes along with hydrazones demonstrate considerable pharmacology activity⁽¹⁵⁾.

A chronic endocrine condition called diabetes mellitus alters how carbohydrates, proteins, fats, electrolytes, and water are metabolised. It comprises a class of metabolic illnesses known as hyperglycemia, in which blood sugar levels are raised due to either insufficient insulin production by the pancreas or ineffective insulin action on the cells⁽¹⁶⁾. Decrease postprandial hyperglycemia as a result is a therapeutic strategy for the management of diabetes⁽¹⁷⁾. This can be accomplished by inhibiting enzymes that hydrolyze carbohydrates, such as alpha amylase and alpha glucosidase⁽¹⁸⁾. Alpha amylase and alpha glucosidase are crucial enzymes in the breakdown of carbohydrates. Long chain carbohydrates are broken down by alpha amylase, while starch and disaccharides are converted to glucose by alpha glucosidase. They assist in intestinal absorption and act as the primary digestive enzymes. Deswal and colleagues synthesised compounds of Co, Ni, Cu, and Zn with the ligand to find possible drugs for the treatment of diabetes. Theoretical calculations and in vitro assays against α -amylase and α -glucosidase demonstrated promising results, with one of the complexes as a good inhibitor of α -amylase and another complex as a strong inhibitor of α -glucosidase. Molecular docking experiments and molecular dynamics simulations supported the observed interactions and stability of the complexes⁽¹⁹⁾. In 2022, Ajaza et al., examined the impact of synthesized Zn(II) complex on diabetes mellitus-2. Antidiabetic activities of the synthesized compounds were also evaluated by performing in vitro α -amylase and α -glucosidase inhibition studies and zinc(II) complexes were also found to be effective against α -amylase only. Similarly a series of silver(I) complexes of 2,4-dihydroxybenzaldehyde–amino acid Schiff bases were tested by Zheng & Ma in 2015 for α -glucosidase inhibition. Obtained results indicate that all the silver complexes possessed strong inhibitory activity. Sn(IV) metal complexes are not investigated for the anti-hyperglycemia activity in prior studies, despite the fact that several metal complexes have been tested for their anti-hyperglycemia activity. The discovery of lead drugs for the treatment of diabetes may focus on alpha amylase and glucosidase inhibitors⁽²⁰⁾.

2 Methodology

Melting points were determined in soft glass capillaries in an electrothermal melting point apparatus. The IR spectra were recorded on FTIR SHIMADZU 8400S spectrometer with KBr pellets. The ¹H-NMR spectrum were recorded in CDCl₃ and DMSO-d₆ at 400 MHz on a Bruker NMR instrument, using TMS as internal standard. FAB mass spectra were recorded on JEOL SX 102 /DA-6000 mass spectrometer using Argon /Xenon as FAB gas.

2.1 Synthesis of 2,3-dimethyl-N'-(2-oxo-2,3-dihydro-1H-indol-3-yl benzhydrazide"(HL)

2.1.1 Step-1: Preparation of 2,3-dimethylbenzoic acid hydrazide precursor

2,3-dimethylbenzoic acid methyl ester (0.01 mole, 1.64 g) was refluxed with methanol solution of hydrazine hydrate 80% (0.25 mole) for 3 hours⁽²¹⁾. The resulting reaction mixture was filtered and washed with distilled water. Obtained solid product was purified with C₂H₅OH and dried in vacuum. Analysis:m.p.124-126⁰C; Yield: 79%; IR (cm⁻¹, KBr): 3225 (-NH), 3035(Ar., -C-H), 1630 (C=O), 1545 (C=C).MS (EI) m/z: 164, 149, 133, 118, 105 etc. Molecular formula calculated as C₉H₁₂N₂O.

2.1.2 Step-2: Preparation of "2,3-dimethyl-N'-(2-oxo-2,3-dihydro-1H-indol-3-yl benzhydrazide"(HL)

0.01 mole of isatin (1.47 g) and 0.01 mole of 2,3-dimethylbenzoic acid hydrazide were taken in 20 ml ethanol solvent. This mixture was refluxed for 4 hrs (22). The solid product obtained was separated by filtration and washed with cold water and then dried in vacuum. Analysis: Shiny light orange color, crystalline solid; m.p. 284–286°C; Yield 82%; IR (cm⁻¹, KBr): 3275 (-NH), 3065(Ar., -C-H), 1724 (C=O, isatin), 1686 (C=O, amido) 1540 (C=N). ¹H NMR (δppm, DMSO-d₆): 12.30 (s, 1H, -NH, isatin), 10.80 (s, 1H, -NH), 6.98-7.11 (m, 7H, Ar-H), 2.49 (s, 3H, -CH₃), 2.31 (s, 3H, -CH₃).MS (EI) m/z: 293, 278, 202, 174, 145 etc. Molecular formula calculated as C₁₇H₁₅N₃O₂.




Fig 1. Synthesis of 2,3-dimethyl-N'-(2-oxo-2,3-dihydro-1H-indol-3-yl) benzohydrazide

2.3 Synthesis of Sn(IV complexes with Ligand (HL)

In the methanolic solution of ligand 2,3-dimethyl-N'-(2-oxo-2,3-dihydro-1H-indol-3-yl)benzhydrazide(6.55 mmol), equimolar Na metal (2.0 mmol) was added with constant stirring. The light yellow colour sodium salt was formed. This salt solution was refluxed under anhydrous condition for 01 hour. This methanolic solution of sodium salt of ligand was added to the anhydrous benzene solution of R_nSnCl_{4-n} (6.55 mmol of n-Bu₃SnCl / n-Bu₂SnCl₂) in 1:1 ratio. The ensuing solution was further refluxed for 06 hours under anhydrous atmosphere. The color of reaction mixture becomes more intense. NaCl produced during reaction was filtrated and concentrated in vacuum, which gave brown to dark brown solid. This solid was purified by re-crystallization with a mixture of dichloromethane and n-hexane under vacuum (23). Yield 89%.

All these synthesized metal complexes found to be hygroscopic in nature & insoluble in organic solvents apart from DMF & DMSO. Their physical and analytical data are given in Tables 1, 2 and 3.

Table 1. Analytical and Physical data of Ligand and its Organotin(IV) complexes

S. No.	Compound	Emp. Formula	Color	M.P. (OC)	Mol. Wt.
1	HL	C ₁₇ H ₁₅ N ₃ O ₂	Light Orange	284-286	293.32
2	n-Bu ₃ Sn(L)	C ₂₉ H ₄₁ N ₃ O ₂ Sn	Pale Brown	>300	582.37
3	n-Bu ₂ Sn(L)Cl	C ₂₅ H ₃₂ ClN ₃ O ₂ Sn	Brown	>300	560.71

Table 2. Important IR spectral data (cm⁻¹, KBr) of ligand and its corresponding organotin(IV) complexes

S. No.	Compounds	ν(NH)	ν(C=N)	ν(C=O)	ν(Sn-C)	ν(Sn-N)	ν(Sn-O)
1	HL	3275	1540	1686 1724	-	-	-
2	n-Bu ₃ Sn(L)	-	1530	-	620	430	548
3	n-Bu ₂ Sn(L)Cl	-	1525	-	632	428	545

Table 3. ¹H NMR spectral data of the ligand and its corresponding organotin(IV) complexes

S.No.	Compounds	Chemical Shift (δ ppm)		
		-NH	Aromatic	Sn-Bu
1	HL	12.30 (s, 1H) 10.80 (s, 1H)	6.98-7.11 (m, 7H)	-
2	n-Bu ₃ Sn(L)	12.45 (s, 1H)	6.82-7.73 (m, 7H)	0.73-1.48 (m, 27H)
3	n-Bu ₂ Sn(L)Cl	12.45 (s, 1H)	6.93-7.85 (m, 7H)	0.96-1.45 (m, 18H)

2.3 Antidiabetic activity

In-vitro antidiabetic activity by using alpha-amylase and alpha-glucosidase inhibition.

2.3.1 Inhibition of alpha-amylase enzyme

A starch solution (0.1% w/v) was obtained by stirring 0.1g of potato starch in 100 ml of 16 mM of sodium acetate buffer. The enzyme solution was prepared by mixing 27.5 mg of alpha-amylase in 100 ml of distilled water. The colorimetric reagent is prepared by mixing sodium potassium tartarate solution and 3, 5 di nitro salicylic acid solution 96 mM. Both control and plant extracts were added with starch solution and left to react with alpha- amylase solution under alkaline conditions at 25°C. The reaction was measured over 3 minutes. The generation of maltose was quantified by the reduction of 3, 5 dinitro salicylic acid to 3-amino-5-nitro salicylic acid. This reaction is detectable at 540 nm⁽²⁴⁾.

2.3.2 Inhibition of alpha-glucosidase enzyme

The inhibitory activity was determined by incubating a solution of starch substrate (2% w/v maltose or sucrose) 1 ml with 0.2 M Tris buffer pH 8.0 and various concentration of plant extract for 5 min at 37°C. The reaction was initiated by adding 1 ml of alpha-glucosidase enzyme (1U/ml) to it followed by incubation for 40 min at 35°C. Then the reaction was terminated by the addition of 2 ml of 6N HCl. Then the intensity of the colour was measured at 540nm⁽²⁴⁾.

Table 4. The percent inhibition of alpha amylase by Ligand (HL) [L-1] andSn(IV) metal complex i.e. n-Bu₃Sn(L) [MC-1] & n-Bu₂Sn(L)Cl [MC-2]at varying concentrations

Concentration (μ g/ml)	% Inhibition by L-1	IC ₅₀ (μ g/ml) (L-1)	% Inhibition by MC-1	IC ₅₀ (μ g/ml) (MC-1)	% Inhibition by MC-2	IC ₅₀ (μ g/ml) (MC-2)
20	8		32		34	
40	28		40		42	
60	32	118.88±11.14	18	70.58±9.66	21	67.58±7.11
80	36		52		55	
100	40		60		60	

Table 5. The percent inhibition of alpha glucosidase by Ligand (HL) [L-1] andSn(IV) metal complex i.e. n-Bu₃Sn(L) [MC-1] & n-Bu₂Sn(L)Cl [MC-2]at varying concentrations

Concentration (μ g/ml)	% Inhibition by L-1	IC ₅₀ (μ g/ml) (L-1)	% Inhibition by MC-1	IC ₅₀ (μ g/ml) (MC-1)	% Inhibition by MC-2	IC ₅₀ (μ g/ml) (MC-2)
20	8.5		29		31	
40	25		37.5		39	
60	29	128.86±10.27	47.6	76.90±9.55	50.3	73.28±8.31
80	33		48.5		55.6	
100	39		59.2		62	

3 Results and Discussion

3.1 Characterization of ligand 2,3-dimethyl-N'-(2-oxo-2,3-dihydro-1H-indol-3-yl) benzhydrazide (HL)

The mass spectrum of this ligand showed a molecular ion peak at m/z 293 $[M^+]$ with other important peak at 278, 202, 174, 145 etc. The molecular formula was determined as $C_{17}H_{15}N_3O_2$ with the help of 1H NMR & elemental investigation. IR spectrum (cm^{-1} , KBr) of compound/ligand confirmed the presence of $-NH$ group by showing absorption at 3275 cm^{-1} . The presence of carbonyl group was established by the absorption at 1724 and 1686 cm^{-1} . The absorption at 1540 indicated the presence of $>C=N$ group. The 1HNMR spectrum (δ ppm, DMSO- d_6) showed sharp two singlets at 12.30 (s, 1H, $-NH$ isatin) and 10.80 (s, 1H, $-NHCO$) which indicated the presence of $-NH$ groups. Two other singlets were observed at 2.49 (s, 3H, $-CH_3$) and at 2.31 (s, 3H, $-CH_3$) for three protons each were ascertained to two methyl groups ($-CH_3$) at position $C3'$ and $C4'$. A multiplet peak was observed between δ 6.98-7.11 (m, 7H, Ar-H) for remaining seven aromatic hydrogen.

The identity of the title compound/ligand was further confirmed by comparing the spectral data with reported values⁽²⁵⁾. On the basis of above observation and discussion this compound/ligand was identified as 2,3-dimethyl-N'-(2-oxo-2,3-dihydro-1H-indol-3-yl)benzhydrazide.




Fig 2. 2,3-dimethyl-N'-(2-oxo-2,3-dihydro-1H-indol-3-yl) benzhydrazide

3.2 Characterization of Sn(IV) complexes

These IR vibrations of all complexes have been compared with spectrum of free ligands and their derivatives. The $-NH$ and $C=O$ absorption bands of amido group which appeared at 3275 cm^{-1} and 1686 cm^{-1} in the spectrum of free ligand, were not detected in spectrum of complexes. The emergence of a new band in IR spectrum of these complexes at 428 & 430 and 545 & 548 cm^{-1} region, assigned to $\nu(Sn-N)$, $\nu(Sn-O)$ also support the coordination of N and O to the tin metal ion respectively⁽²⁶⁾. The new $\nu(C=N)$ mode observed at 1530 cm^{-1} in spectra of hydrazones undergoes little shifts in spectrum of the complexes recommend that N atom of the ligand moiety affixed to the indole ring also coordinating to metal ion in complexes formation. The above IR spectral data is indicated that, all the above mentioned complexes Sn, the ligand appeared to bind with metal via N and O in tridentate fashion.

The expected 1HNMR spectral (δ ppm, DMSO- d_6) information of ligand and their metal complexes are depicted. The signal appeared at δ 10.80 (s, 1H, $-NHCO$) due to $-NH$ proton in free ligand spectrum, was absent in spectra of all these complexes, suggested that deprotonation was taken place during the complexation and ligand attached to the Sn in neutral form. The other protons of ligand moiety like aromatic protons were appeared as a multiplet in the region δ 6.82-8.10 ppm in spectrum of complexes and almost same as ligand. Based on these observed chemical shift difference, it is assumed that coordination number of Sn in this complex is six⁽²⁷⁾.

3.3 Anti-hyperglycemia Activity

The results of this study's investigation into the inhibitory activity of Ligand (HL) [L-1] and Sn(IV) metal complex, specifically $n-Bu_3Sn(L)$ [MC-1] & $n-Bu_2Sn(L)Cl$ [MC-2], on alpha amylase and alpha glucosidase are displayed in Tables 4 and 5. L-1 (118.88 ± 11.14), MC-1 (76.90 ± 9.55), and MC-2 (73.28 ± 8.31) all demonstrated 50% alpha amylase inhibition activity in the alpha amylase inhibition assay. L-1 had the least inhibitory action, followed by MC-1 and MC-2 who all shown good anti-alpha amylase activity. All of the substances increased their % inhibitory activity against alpha glucosidase in a dose-dependent manner. In the alpha glucosidase inhibition assay, [L-1], [MC-1], and [MC-2] had IC_{50} values of 128.86 ± 10.27 , 76.90 ± 9.55 , and 73.28 ± 8.31 g/ml, respectively. Alpha glucosidase enzyme inhibition was more pronounced in MC-2.

4 Conclusion

The synthesized complex was characterized using various physico and spectrochemical techniques. The coordination sites are confirmed by using ¹H-NMR and FT-IR. Based on these observed chemical shift difference, it is assumed that coordination number of Sn(IV) in this complex is six. Because of their distinctive properties and uncommon reactivity, Schiff base complexes can be used as a building block to create complex compounds with potential uses across a wide range of industries. L-1 (118.88±11.14), MC-1 (76.90±9.55), and MC-2 (73.28±8.31) all showed 50% alpha amylase inhibition activity in the alpha amylase inhibition assay, while their respective IC₅₀ values for [L-1], [MC-1], and [MC-2] in the alpha glucosidase inhibition experiment were 128.86±10.27, 76.90±9.55, and 73.28±8.31 g/ml. The study's conclusions suggested that MC-2 might be helpful in the treatment of postprandial hyperglycemia. When compared to alpha amylase, Sn(IV) metal complexes caused a slightly less potent alpha glucosidase enzyme inhibition. These unusual and novel characteristics open up a whole new field of study for the investigation of their potential biological, analytical, and therapeutic uses.

Acknowledgement

Authors wish to thank Head, Department of Chemistry, University of Rajasthan, Jaipur Rajasthan, INDIA for providing Laboratory facilities.

References

- 1) Annuar SNS, Kamaludin NF, Awang N, Chan KM. Cellular Basis of Organotin(IV) Derivatives as Anticancer Metallo-drugs: A Review. *Frontiers in Chemistry*. 2021;9:657599. Available from: <https://doi.org/10.3389/fchem.2021.657599>.
- 2) De Paiva REF, Vieira EG, Silva DRD, Wegermann CA, Ferreira AMC. Anticancer Compounds Based on Isatin-Derivatives: Strategies to Ameliorate Selectivity and Efficiency. *Frontiers in Molecular Biosciences*. 2021;7. Available from: <https://doi.org/10.3389/fmolb.2020.627272>.
- 3) Simanjuntak W, Qudus HI, Hadi S. The potential of derivatives of organotin (IV) benzoate compounds in medicinal chemistry. *Journal of Physics: Conference Series*. 2019;1338:12014. Available from: <https://doi.org/10.1088/1742-6596/1338/1/012014>.
- 4) Kumar N, Asija S, Deswal Y, Saroya S, Kumar A. Development of new tridentate ligands bearing hydrazone motif and their diorganotin(IV) complexes: Synthesis, spectral, antimicrobial and molecular docking studies. *Research on Chemical Intermediates*. 2022;48(12):5133–5154. Available from: <https://doi.org/10.1007/s11164-022-04860-0>.
- 5) Huentupil Y, Peña L, Novoa N, Berrino E, Arancibia R, Supuran CT. New sulfonamides containing organometallic-acylhydrazones: synthesis, characterisation and biological evaluation as inhibitors of human carbonic anhydrases. *Journal of Enzyme Inhibition and Medicinal Chemistry*. 2019;34(1):451–458. Available from: <https://doi.org/10.1080/14756366.2018.1555156>.
- 6) Adeyemi OS, Eseola AO, Plass W, Atolani O, Sugi T, Han Y, et al. Imidazole derivatives as antiparasitic agents and use of molecular modeling to investigate the structure–activity relationship. *Parasitology Research*. 2020;119(6):1925–1941. Available from: <https://doi.org/10.1007/s00436-020-06668-6>.
- 7) Hadi S, Fenska MD, Wijaya RA, Noviany N, Suhartati T. Antimalarial Activity of Some Organotin(IV) Chlorobenzoate Compounds against Plasmodium falciparum. *Mediterranean Journal of Chemistry*. 2020;10(3):213–219. Available from: <https://doi.org/10.13171/mjc0200312162sh>.
- 8) Saroya S, Asija S, Deswal Y, Kumar N, Kumar A. Synthesis, spectral studies, in vitro antimicrobial activity and molecular docking studies of organotin(IV) complexes derived from tridentate Schiff base ligands. *Research on Chemical Intermediates*. 2022;48(7):2949–2971. Available from: <https://doi.org/10.1007/s11164-022-04731-8>.
- 9) Gaber M, El-Wakiel N, El-Baradie K, Hafez S. Chromone Schiff base complexes: synthesis, structural elucidation, molecular modeling, antitumor, antimicrobial, and DNA studies of Co(II), Ni(II), and Cu(II) complexes. *Journal of the Iranian Chemical Society*. 2019;16(1):169–182. Available from: <https://doi.org/10.1007/s13738-018-1494-9>.
- 10) Saroya S, Asija S, Deswal Y, Kumar N, Kumar D, Jindal DK, et al. Pentacoordinated diorganotin(IV) complexes of Schiff base ligands: synthesis, characterization, antimicrobial and anticancer studies. *Research on Chemical Intermediates*. 2022;48(11):4671–4691. Available from: <https://doi.org/10.1007/s11164-022-04826-2>.
- 11) Saroya S, Asija S, Kumar N, Deswal Y, Devi J. Organotin (IV) complexes derived from tridentate Schiff base ligands: Synthesis, spectroscopic analysis, antimicrobial and antioxidant activity. *Journal of the Indian Chemical Society*. 2022;99(3):100379. Available from: <https://doi.org/10.1016/j.jics.2022.100379>.
- 12) Sun Y, Lu Y, Bian M, Yang Z, Ma X, Liu WX. Pt(II) and Au(III) complexes containing Schiff-base ligands: A promising source for antitumor treatment. *European Journal of Medicinal Chemistry*. 2021;211:113098. Available from: <https://doi.org/10.1016/j.ejmech.2020.113098>.
- 13) Agarwal P, Asija S, Deswal Y, Kumar N. Recent advancements in the anticancer potentials of first row transition metal complexes. *Journal of the Indian Chemical Society*. 2022;99(8):100556. Available from: <https://doi.org/10.1016/j.jics.2022.100556>.
- 14) Deswal Y, Asija S, Kumar D, Jindal DK, Chandan G, Panwar V, et al. Transition metal complexes of triazole-based bioactive ligands: synthesis, spectral characterization, antimicrobial, anticancer and molecular docking studies. *Research on Chemical Intermediates*. 2022;48(2):703–729. Available from: <https://doi.org/10.1007/s11164-021-04621-5>.
- 15) Kumar N, Asija S, Deswal Y, Saroya S, Kumar A, Devi J. Organotin(IV) complexes derived from hydrazone ligands: Synthesis, spectral analysis, antimicrobial and molecular docking studies. *Phosphorus, Sulfur, and Silicon and the Related Elements*. 2022;197(9):952–963. Available from: <https://doi.org/10.1080/10426507.2022.2048386>.
- 16) Patle D, Vyas M, Khatik GL. A Review on Natural Products and Herbs Used in the Management of Diabetes. *Current Diabetes Reviews*. 2021;17(2):186–197. Available from: <https://doi.org/10.2174/1573399816666200408090058>.
- 17) Korytkowski MT, Muniyappa R, Antinori-Lent K, Donihi AC, Drincic AT, Hirsch IB, et al. Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*. 2022;107(8):2101–2128. Available from: <https://doi.org/10.1210/clinem/dgac278>.

- 18) Kato-Schwartz CG, Corrêa RCG, Lima DDS, De Sá-Nakanishi AB, Gonçalves GDA, Seixas FAV, et al. Potential anti-diabetic properties of Merlot grape pomace extract: An in vitro, in silico and in vivo study of α -amylase and α -glucosidase inhibition. *Food Research International*. 2020;137:109462. Available from: <https://doi.org/10.1016/j.foodres.2020.109462>.
- 19) Deswal Y, Asija S, Tufail A, Dubey A, Deswal L, Kumar N, et al. Instigating the in vitro antidiabetic activity of new tridentate Schiff base ligand appended M(II) complexes: From synthesis, structural characterization, quantum computational calculations to molecular docking, and molecular dynamics simulation studies. *Applied Organometallic Chemistry*. 2023;37(4). Available from: <https://doi.org/10.1002/aoc.7050>.
- 20) Proença C, Ribeiro D, Freitas M, Fernandes E. Flavonoids as potential agents in the management of type 2 diabetes through the modulation of α -amylase and α -glucosidase activity: a review. *Critical Reviews in Food Science and Nutrition*. 2022;62(12):3137–3207. Available from: <https://doi.org/10.1080/10408398.2020.1862755>.
- 21) Bhaskar RS, Ladole CA, Salunkhe NG, Barabde JM, Aswar AS. Synthesis, characterization and antimicrobial studies of novel ONO donor hydrazone Schiff base complexes with some divalent metal (II) ions. *Arabian Journal of Chemistry*. 2020;13(8):6559–6567. Available from: <https://doi.org/10.1016/j.arabjc.2020.06.012>.
- 22) Alorini TA, Al-Hakimi AN, Saeed SES, Alhamzi EHL, Albadri AEAE. Synthesis, characterization, and anticancer activity of some metal complexes with a new Schiff base ligand. *Arabian Journal of Chemistry*. 2022;15(2):103559. Available from: <https://doi.org/10.1016/j.arabjc.2021.103559>.
- 23) Howsai HB, Sharfalddin AA, Abdellattif MH, Basaleh AS, Hussien MA. Ni (II), Co (II) and Zn (II) complexes with new Schiff Base of 2-((Pyrazine-2-ylimino) methyl) phenol. *Applied Sciences*. 2021;11:9067. Available from: <https://doi.org/10.3390/app11199067>.
- 24) Momina SS, Vanapatla Swaroopa Rani. In vitro Studies on α -Amylase and α -Glucosidase Inhibitory Activity of Some Bioactive Extracts. *Journal of Young Pharmacists*. 2020;12(2s):s72–s75. Available from: <https://doi.org/10.5530/jyp.2020.12s.50>.
- 25) Deswal Y, Asija S, Dubey A, Deswal L, Kumar D, Jindal DK, et al. Cobalt(II), nickel(II), copper(II) and zinc(II) complexes of thiazazole based Schiff base ligands: Synthesis, structural characterization, DFT, antidiabetic and molecular docking studies. *Journal of Molecular Structure*. 2022;1253:132266. Available from: <https://doi.org/10.1016/j.molstruc.2021.132266>.
- 26) Sharma V, Agrawal S, Bohra R, Ratnani R, Drake JE, Bingham AL, et al. Synthesis and characterization of some monoorganotin(IV) chloride adducts with internally functionalized oximes: Crystal and molecular structures of nBuSnCl₃·HONC(Me)Py-2·C₆H₅Me and a trinuclear hydroxo bridged stannoxane {nBuSnCl₂(ONC(Me)Py-2)OH}₂SnnBuCl·0.5HONC(Me)Py-2. *Inorganica Chimica Acta*. 2006;359(5):1404–1412. Available from: <https://doi.org/10.1016/j.ica.2005.09.017>.
- 27) Devi J, Yadav J, Singh NJ. Synthesis, characterisation, in vitro antimicrobial, antioxidant and anti-inflammatory activities of diorganotin(IV) complexes derived from salicylaldehyde Schiff bases. *Research on Chemical Intermediates*. 2019;45(7):3943–3968. Available from: <https://doi.org/10.1007/s11164-019-03830-3>.